Global Mantle Cell Lymphoma Treatment Market

Mantle Cell Lymphoma Treatment Comprehensive Study by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11, Others), Application (Hospital, Clinic, Others), Route of Administration (Oral, Intravenous, Others), Therapy Type (Targeted Therapy, Chemotherapy, Biologics, Radiotherapy) Players and Region - Global Market Outlook to 2030

Mantle Cell Lymphoma Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Mantle Cell Lymphoma Treatment Market Scope?
Mantle cell lymphoma is a rare form of B-cell non-Hodgkin lymphoma (NHL). It is a type of blood cancer, which affects white blood cells called lymphocytes. Lymphocytes are white blood cells which help fight diseases in the body and other infections. The disease gets its name as it affects lymphocytes in the mantle zone of a lymph node. Lymphocytes are found mostly in the lymphatic system, which includes lymph nodes, spleen, and bone marrow. MCL cells can spread to other lymph nodes or tissues, such as the gastrointestinal liver, tract, and marrow. Common symptoms of the disease include abdominal pain or bloating, loss of appetite & weight loss, fever, nausea and/or vomiting, night sweats, indigestion, and feeling discomfort. The type of treatment for a patient suffering from MCL depends on various factors such as the overall health of the patient, age, and disease stage.

Influencing Trend:
Chemotherapy with an Antibody Treatment Called Rituximab and Introduction of New Drugs for the Treatment of Mantle Cell Lymphoma Treatment

Market Growth Drivers:
The rise in the Number of People Suffering From Mantle Cell Lymphoma, Increase in Research and Development Activities in the Health Care Sector and Development of Targeted Therapy Drugs with Low Toxicity

Challenges:
Resistance to traditional therapies like chemotherapy can develop, limiting treatment options.

Restraints:
Side Effects of the Drugs Such As Neutropenia, Anemia, and Diarrhea

Opportunities:
Rising Geriatric Population Worldwide

The Mantle Cell Lymphoma Treatment market study is being classified by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11 and Others), by Application and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Mantle Cell Lymphoma Treatment market throughout the predicted period.

Astex Pharmaceuticals, Inc. (United Kingdom), Bayer AG (Germany), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), Cellular Biomedicine Group, Inc. (United States), Eisai (Japan), EpiZyme, Inc. (United States), Fate Therapeutics, Inc. (United States) and Genentech, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Gilead Sciences, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Hutchison MediPharma Limited (China), ImmunoGen, Inc. (United States) and Immunomedics, Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Mantle Cell Lymphoma Treatment market by Type, Application and Region.

On the basis of geography, the market of Mantle Cell Lymphoma Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
On 17 June, 2019, Cellular Biomedicine Group Inc., a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, has announced that it has initiated its Phase I Clinical Trial of anti-CD20 Chimeric Antigen Receptor T-cell ("CAR-T") targeting anti-CD19 treated, relapsed diffuse large B-cell lymphoma ("DLBCL") and small B-cell lymphoma patients in China, and dosed the first CD19 CAR-T relapsed DLBCL patient.
In January 2023, the Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.


Key Target Audience
Mantle Cell Lymphoma Companies, Mantle Cell Lymphoma Drugs Manufacturers, Mantle Cell Lymphoma Drugs Traders/Distributors, Mantle Cell Lymphoma Drugs Importer/Exporter, Research and Consulting Firms, Regulatory & Government Bodies, End Users and Others

Mantle Cell Lymphoma Treatment Market Study: Important Years
AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Mantle Cell Lymphoma Treatment Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Mantle Cell Lymphoma Treatment industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Acalabrutinib
  • JCAR-017
  • JNJ-64052781
  • Acalisib
  • IGN-002
  • IMGN-529
  • AFM-11
  • Others
By Application
  • Hospital
  • Clinic
  • Others
By Route of Administration
  • Oral
  • Intravenous
  • Others

By Therapy Type
  • Targeted Therapy
  • Chemotherapy
  • Biologics
  • Radiotherapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise in the Number of People Suffering From Mantle Cell Lymphoma
      • 3.2.2. Increase in Research and Development Activities in the Health Care Sector
      • 3.2.3. Development of Targeted Therapy Drugs with Low Toxicity
    • 3.3. Market Challenges
      • 3.3.1. Resistance to traditional therapies like chemotherapy can develop, limiting treatment options.
    • 3.4. Market Trends
      • 3.4.1. Chemotherapy with an Antibody Treatment Called Rituximab
      • 3.4.2. Introduction of New Drugs for the Treatment of Mantle Cell Lymphoma Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mantle Cell Lymphoma Treatment, by Type, Application, Route of Administration, Therapy Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Mantle Cell Lymphoma Treatment (Value)
      • 5.2.1. Global Mantle Cell Lymphoma Treatment by: Type (Value)
        • 5.2.1.1. Acalabrutinib
        • 5.2.1.2. JCAR-017
        • 5.2.1.3. JNJ-64052781
        • 5.2.1.4. Acalisib
        • 5.2.1.5. IGN-002
        • 5.2.1.6. IMGN-529
        • 5.2.1.7. AFM-11
        • 5.2.1.8. Others
      • 5.2.2. Global Mantle Cell Lymphoma Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Mantle Cell Lymphoma Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Others
      • 5.2.4. Global Mantle Cell Lymphoma Treatment by: Therapy Type (Value)
        • 5.2.4.1. Targeted Therapy
        • 5.2.4.2. Chemotherapy
        • 5.2.4.3. Biologics
        • 5.2.4.4. Radiotherapy
      • 5.2.5. Global Mantle Cell Lymphoma Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Mantle Cell Lymphoma Treatment (Price)
      • 5.3.1. Global Mantle Cell Lymphoma Treatment by: Type (Price)
  • 6. Mantle Cell Lymphoma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astex Pharmaceuticals, Inc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celgene Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cellular Biomedicine Group, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eisai (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. EpiZyme, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fate Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Genentech, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Mantle Cell Lymphoma Treatment Sale, by Type, Application, Route of Administration, Therapy Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Mantle Cell Lymphoma Treatment (Value)
      • 7.2.1. Global Mantle Cell Lymphoma Treatment by: Type (Value)
        • 7.2.1.1. Acalabrutinib
        • 7.2.1.2. JCAR-017
        • 7.2.1.3. JNJ-64052781
        • 7.2.1.4. Acalisib
        • 7.2.1.5. IGN-002
        • 7.2.1.6. IMGN-529
        • 7.2.1.7. AFM-11
        • 7.2.1.8. Others
      • 7.2.2. Global Mantle Cell Lymphoma Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Mantle Cell Lymphoma Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Others
      • 7.2.4. Global Mantle Cell Lymphoma Treatment by: Therapy Type (Value)
        • 7.2.4.1. Targeted Therapy
        • 7.2.4.2. Chemotherapy
        • 7.2.4.3. Biologics
        • 7.2.4.4. Radiotherapy
      • 7.2.5. Global Mantle Cell Lymphoma Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Mantle Cell Lymphoma Treatment (Price)
      • 7.3.1. Global Mantle Cell Lymphoma Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mantle Cell Lymphoma Treatment: by Type(USD Million)
  • Table 2. Mantle Cell Lymphoma Treatment Acalabrutinib , by Region USD Million (2018-2023)
  • Table 3. Mantle Cell Lymphoma Treatment JCAR-017 , by Region USD Million (2018-2023)
  • Table 4. Mantle Cell Lymphoma Treatment JNJ-64052781 , by Region USD Million (2018-2023)
  • Table 5. Mantle Cell Lymphoma Treatment Acalisib , by Region USD Million (2018-2023)
  • Table 6. Mantle Cell Lymphoma Treatment IGN-002 , by Region USD Million (2018-2023)
  • Table 7. Mantle Cell Lymphoma Treatment IMGN-529 , by Region USD Million (2018-2023)
  • Table 8. Mantle Cell Lymphoma Treatment AFM-11 , by Region USD Million (2018-2023)
  • Table 9. Mantle Cell Lymphoma Treatment Others , by Region USD Million (2018-2023)
  • Table 10. Mantle Cell Lymphoma Treatment: by Application(USD Million)
  • Table 11. Mantle Cell Lymphoma Treatment Hospital , by Region USD Million (2018-2023)
  • Table 12. Mantle Cell Lymphoma Treatment Clinic , by Region USD Million (2018-2023)
  • Table 13. Mantle Cell Lymphoma Treatment Others , by Region USD Million (2018-2023)
  • Table 14. Mantle Cell Lymphoma Treatment: by Route of Administration(USD Million)
  • Table 15. Mantle Cell Lymphoma Treatment Oral , by Region USD Million (2018-2023)
  • Table 16. Mantle Cell Lymphoma Treatment Intravenous , by Region USD Million (2018-2023)
  • Table 17. Mantle Cell Lymphoma Treatment Others , by Region USD Million (2018-2023)
  • Table 18. Mantle Cell Lymphoma Treatment: by Therapy Type(USD Million)
  • Table 19. Mantle Cell Lymphoma Treatment Targeted Therapy , by Region USD Million (2018-2023)
  • Table 20. Mantle Cell Lymphoma Treatment Chemotherapy , by Region USD Million (2018-2023)
  • Table 21. Mantle Cell Lymphoma Treatment Biologics , by Region USD Million (2018-2023)
  • Table 22. Mantle Cell Lymphoma Treatment Radiotherapy , by Region USD Million (2018-2023)
  • Table 23. South America Mantle Cell Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 24. South America Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 25. South America Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 26. South America Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 27. South America Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 28. Brazil Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 29. Brazil Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 30. Brazil Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 31. Brazil Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 32. Argentina Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 33. Argentina Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 34. Argentina Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 35. Argentina Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 36. Rest of South America Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 37. Rest of South America Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 38. Rest of South America Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 39. Rest of South America Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 40. Asia Pacific Mantle Cell Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 44. Asia Pacific Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 45. China Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 46. China Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 47. China Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 48. China Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 49. Japan Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 50. Japan Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 51. Japan Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 52. Japan Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 53. India Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 54. India Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 55. India Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 56. India Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 57. South Korea Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 58. South Korea Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 59. South Korea Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 60. South Korea Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 61. Taiwan Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 62. Taiwan Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 63. Taiwan Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 64. Taiwan Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 65. Australia Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 66. Australia Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 67. Australia Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 68. Australia Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 72. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 73. Europe Mantle Cell Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 74. Europe Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 75. Europe Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 76. Europe Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 77. Europe Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 78. Germany Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 79. Germany Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 80. Germany Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 81. Germany Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 82. France Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 83. France Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 84. France Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 85. France Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 86. Italy Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 87. Italy Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 88. Italy Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 89. Italy Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 90. United Kingdom Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 91. United Kingdom Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 92. United Kingdom Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 93. United Kingdom Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 94. Netherlands Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 95. Netherlands Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 96. Netherlands Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 97. Netherlands Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 98. Rest of Europe Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 99. Rest of Europe Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 100. Rest of Europe Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 101. Rest of Europe Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 102. MEA Mantle Cell Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 103. MEA Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 104. MEA Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 105. MEA Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 106. MEA Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 107. Middle East Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 108. Middle East Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 109. Middle East Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 110. Middle East Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 111. Africa Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 112. Africa Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 113. Africa Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 114. Africa Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 115. North America Mantle Cell Lymphoma Treatment, by Country USD Million (2018-2023)
  • Table 116. North America Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 117. North America Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 118. North America Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 119. North America Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 120. United States Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 121. United States Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 122. United States Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 123. United States Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 124. Canada Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 125. Canada Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 126. Canada Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 127. Canada Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 128. Mexico Mantle Cell Lymphoma Treatment, by Type USD Million (2018-2023)
  • Table 129. Mexico Mantle Cell Lymphoma Treatment, by Application USD Million (2018-2023)
  • Table 130. Mexico Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2018-2023)
  • Table 131. Mexico Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2018-2023)
  • Table 132. Mantle Cell Lymphoma Treatment: by Type(USD/Units)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Mantle Cell Lymphoma Treatment: by Type(USD Million)
  • Table 143. Mantle Cell Lymphoma Treatment Acalabrutinib , by Region USD Million (2025-2030)
  • Table 144. Mantle Cell Lymphoma Treatment JCAR-017 , by Region USD Million (2025-2030)
  • Table 145. Mantle Cell Lymphoma Treatment JNJ-64052781 , by Region USD Million (2025-2030)
  • Table 146. Mantle Cell Lymphoma Treatment Acalisib , by Region USD Million (2025-2030)
  • Table 147. Mantle Cell Lymphoma Treatment IGN-002 , by Region USD Million (2025-2030)
  • Table 148. Mantle Cell Lymphoma Treatment IMGN-529 , by Region USD Million (2025-2030)
  • Table 149. Mantle Cell Lymphoma Treatment AFM-11 , by Region USD Million (2025-2030)
  • Table 150. Mantle Cell Lymphoma Treatment Others , by Region USD Million (2025-2030)
  • Table 151. Mantle Cell Lymphoma Treatment: by Application(USD Million)
  • Table 152. Mantle Cell Lymphoma Treatment Hospital , by Region USD Million (2025-2030)
  • Table 153. Mantle Cell Lymphoma Treatment Clinic , by Region USD Million (2025-2030)
  • Table 154. Mantle Cell Lymphoma Treatment Others , by Region USD Million (2025-2030)
  • Table 155. Mantle Cell Lymphoma Treatment: by Route of Administration(USD Million)
  • Table 156. Mantle Cell Lymphoma Treatment Oral , by Region USD Million (2025-2030)
  • Table 157. Mantle Cell Lymphoma Treatment Intravenous , by Region USD Million (2025-2030)
  • Table 158. Mantle Cell Lymphoma Treatment Others , by Region USD Million (2025-2030)
  • Table 159. Mantle Cell Lymphoma Treatment: by Therapy Type(USD Million)
  • Table 160. Mantle Cell Lymphoma Treatment Targeted Therapy , by Region USD Million (2025-2030)
  • Table 161. Mantle Cell Lymphoma Treatment Chemotherapy , by Region USD Million (2025-2030)
  • Table 162. Mantle Cell Lymphoma Treatment Biologics , by Region USD Million (2025-2030)
  • Table 163. Mantle Cell Lymphoma Treatment Radiotherapy , by Region USD Million (2025-2030)
  • Table 164. South America Mantle Cell Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 165. South America Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 166. South America Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 167. South America Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 168. South America Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 169. Brazil Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 170. Brazil Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 171. Brazil Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 172. Brazil Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 173. Argentina Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 174. Argentina Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 175. Argentina Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 176. Argentina Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 177. Rest of South America Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 178. Rest of South America Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 179. Rest of South America Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 180. Rest of South America Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 181. Asia Pacific Mantle Cell Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 182. Asia Pacific Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 183. Asia Pacific Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 184. Asia Pacific Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 185. Asia Pacific Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 186. China Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 187. China Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 188. China Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 189. China Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 190. Japan Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 191. Japan Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 192. Japan Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 193. Japan Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 194. India Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 195. India Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 196. India Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 197. India Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 198. South Korea Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 199. South Korea Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 200. South Korea Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 201. South Korea Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 202. Taiwan Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 203. Taiwan Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 204. Taiwan Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 205. Taiwan Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 206. Australia Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 207. Australia Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 208. Australia Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 209. Australia Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 212. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 213. Rest of Asia-Pacific Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 214. Europe Mantle Cell Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 215. Europe Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 216. Europe Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 217. Europe Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 218. Europe Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 219. Germany Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 220. Germany Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 221. Germany Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 222. Germany Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 223. France Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 224. France Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 225. France Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 226. France Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 227. Italy Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 228. Italy Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 229. Italy Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 230. Italy Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 231. United Kingdom Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 232. United Kingdom Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 233. United Kingdom Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 234. United Kingdom Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 235. Netherlands Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 236. Netherlands Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 237. Netherlands Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 238. Netherlands Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 239. Rest of Europe Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 240. Rest of Europe Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 241. Rest of Europe Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 242. Rest of Europe Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 243. MEA Mantle Cell Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 244. MEA Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 245. MEA Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 246. MEA Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 247. MEA Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 248. Middle East Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 249. Middle East Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 250. Middle East Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 251. Middle East Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 252. Africa Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 253. Africa Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 254. Africa Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 255. Africa Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 256. North America Mantle Cell Lymphoma Treatment, by Country USD Million (2025-2030)
  • Table 257. North America Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 258. North America Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 259. North America Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 260. North America Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 261. United States Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 262. United States Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 263. United States Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 264. United States Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 265. Canada Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 266. Canada Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 267. Canada Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 268. Canada Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 269. Mexico Mantle Cell Lymphoma Treatment, by Type USD Million (2025-2030)
  • Table 270. Mexico Mantle Cell Lymphoma Treatment, by Application USD Million (2025-2030)
  • Table 271. Mexico Mantle Cell Lymphoma Treatment, by Route of Administration USD Million (2025-2030)
  • Table 272. Mexico Mantle Cell Lymphoma Treatment, by Therapy Type USD Million (2025-2030)
  • Table 273. Mantle Cell Lymphoma Treatment: by Type(USD/Units)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mantle Cell Lymphoma Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Mantle Cell Lymphoma Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Mantle Cell Lymphoma Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Mantle Cell Lymphoma Treatment: by Therapy Type USD Million (2018-2023)
  • Figure 8. South America Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 9. Asia Pacific Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 10. Europe Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 11. MEA Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 12. North America Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 13. Global Mantle Cell Lymphoma Treatment: by Type USD/Units (2018-2023)
  • Figure 14. Global Mantle Cell Lymphoma Treatment share by Players 2023 (%)
  • Figure 15. Global Mantle Cell Lymphoma Treatment share by Players (Top 3) 2023(%)
  • Figure 16. Global Mantle Cell Lymphoma Treatment share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Astex Pharmaceuticals, Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Astex Pharmaceuticals, Inc. (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 22. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 24. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 25. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 26. Cellular Biomedicine Group, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Cellular Biomedicine Group, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Eisai (Japan) Revenue: by Geography 2023
  • Figure 30. EpiZyme, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. EpiZyme, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Fate Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Fate Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Genentech, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Global Mantle Cell Lymphoma Treatment: by Type USD Million (2025-2030)
  • Figure 37. Global Mantle Cell Lymphoma Treatment: by Application USD Million (2025-2030)
  • Figure 38. Global Mantle Cell Lymphoma Treatment: by Route of Administration USD Million (2025-2030)
  • Figure 39. Global Mantle Cell Lymphoma Treatment: by Therapy Type USD Million (2025-2030)
  • Figure 40. South America Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 41. Asia Pacific Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 42. Europe Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 43. MEA Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 44. North America Mantle Cell Lymphoma Treatment Share (%), by Country
  • Figure 45. Global Mantle Cell Lymphoma Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Astex Pharmaceuticals, Inc. (United Kingdom)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (United States)
  • Celgene Corporation (United States)
  • Cellular Biomedicine Group, Inc. (United States)
  • Eisai (Japan)
  • EpiZyme, Inc. (United States)
  • Fate Therapeutics, Inc. (United States)
  • Genentech, Inc. (United States)
Additional players considered in the study are as follows:
Gilead Sciences, Inc. (United States) , GlaxoSmithKline Plc (United Kingdom) , Hutchison MediPharma Limited (China) , ImmunoGen, Inc. (United States) , Immunomedics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 244 Pages 56 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Mantle Cell Lymphoma Treatment Market Quantitative research analysis
Global Mantle Cell Lymphoma Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Mantle Cell Lymphoma Treatment market are Astex Pharmaceuticals, Inc. (United Kingdom), Bayer AG (Germany), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), Cellular Biomedicine Group, Inc. (United States), Eisai (Japan), EpiZyme, Inc. (United States), Fate Therapeutics, Inc. (United States) and Genentech, Inc. (United States).
In this highly competitive & fast evolving Mantle Cell Lymphoma Treatment industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Hospital, Clinic and Others are the potential customers of Mantle Cell Lymphoma Treatment industry.

Know More About Global Mantle Cell Lymphoma Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Non-alcoholic Steatohepatitis Comprehensive Study by Type (Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, Others), Application (Hypertension, Heart Disease, High Blood Lipid, Diabetes, Obesity), En...
$ 3450
Ophthalmology Drugs Comprehensive Study by Type (Lucentis (Ranibizumab), Eylea (Aflibercept), Avastin (Bevacizumab), Restasis (Cyclosporine), Alphagan (Brimonidine Tartrate), Lumigan (Bimatoprost), X...
$ 3750
Hodgkin Lymphoma Treatment Comprehensive Study by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), Application (Hospital, Clinic, Research Center), Treatment (Immunotherapy, Ra...
$ 3650
Cervical Cancer Diagnostic Tests Comprehensive Study by Type (Pap Test, HPV Typing Test, Colposcopy, Biopsy, Bimanual Pelvic Examination), Application (Hospitals, Specialty Clinics, Cancer and Radiat...
$ 3450
Overactive Bladder Treatment Comprehensive Study by Type (Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training), Therapies (Biofeedback, Kegel Exercise), Medications (Blad...
$ 3750
Ankylosing Spondylitis Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral), Treatment Type (Nonsteroidal Anti-Inflammatory...
$ 3750